Pharvaris N.V. (NASDAQ:PHVS) Given Average Recommendation of "Hold" by Analysts

Shares of Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) have been assigned a consensus recommendation of "Hold" from the seven analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $32.60.

PHVS has been the subject of a number of research reports. Bank of America upgraded Pharvaris from an "underperform" rating to a "neutral" rating and increased their price objective for the stock from $16.00 to $27.00 in a report on Thursday, October 9th. JMP Securities decreased their price objective on Pharvaris from $55.00 to $52.00 and set a "market outperform" rating for the company in a report on Wednesday, August 13th. Zacks Research upgraded Pharvaris from a "strong sell" rating to a "hold" rating in a report on Monday, August 18th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Pharvaris in a report on Wednesday, October 8th.

Hedge Funds Weigh In On Pharvaris

Several institutional investors and hedge funds have recently modified their holdings of the stock. TFG Asset Management GP Ltd increased its holdings in shares of Pharvaris by 48.1% during the second quarter. TFG Asset Management GP Ltd now owns 188,100 shares of the company's stock valued at $3,311,000 after acquiring an additional 61,105 shares in the last quarter. TD Asset Management Inc increased its holdings in shares of Pharvaris by 27.4% during the second quarter. TD Asset Management Inc now owns 99,510 shares of the company's stock valued at $1,751,000 after acquiring an additional 21,388 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Pharvaris by 41.1% during the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company's stock valued at $952,000 after acquiring an additional 15,769 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Pharvaris by 19.2% during the second quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company's stock valued at $860,000 after acquiring an additional 7,879 shares in the last quarter. Finally, Deutsche Bank AG increased its holdings in shares of Pharvaris by 55.1% during the first quarter. Deutsche Bank AG now owns 28,174 shares of the company's stock valued at $442,000 after acquiring an additional 10,006 shares in the last quarter.

Pharvaris Trading Up 0.4%

PHVS opened at $22.07 on Tuesday. The stock has a fifty day simple moving average of $22.97 and a two-hundred day simple moving average of $19.24. The company has a market cap of $1.15 billion, a price-to-earnings ratio of -6.57 and a beta of -2.77. Pharvaris has a 12-month low of $11.51 and a 12-month high of $26.33.

Pharvaris (NASDAQ:PHVS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.87) by ($0.07). On average, analysts predict that Pharvaris will post -2.71 EPS for the current year.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.